UnitedHealth Group
UNH
$375.93
-1.99%
UnitedHealth Group is the largest private health insurer in the United States, providing medical benefits to roughly 51 million members globally through its UnitedHealthcare segment while operating a sprawling healthcare services ecosystem — pharmacy benefits, outpatient care delivery, and data analytics — under its Optum franchises. The company's dual-engine structure, combining insurance scale with vertically integrated care delivery and pharmacy services, makes it a uniquely dominant platform in the managed care industry rather than a pure-play insurer. The current investor narrative is defined by a sharp operational recovery following a turbulent 2025, when medical cost trends and a DOJ investigation pressured results; the stock has rallied dramatically off its lows as margins have snapped back, with Q1 2026 net income of $6.28 billion and EPS of $6.90 signaling a return to normalized profitability. Debate now centers on whether the recovery is fully priced in after the stock's roughly 80% move off its low, and whether the unresolved regulatory overhang and elevated medical cost environment pose renewed risk to the earnings trajectory.…
UNH
UnitedHealth Group
$375.93
Related headlines
Investment Opinion: Should I buy UNH Today?
Rating: Hold. UnitedHealth presents a balanced risk/reward at current levels, with the analyst consensus of 'buy' and average target price of $475.23 implying 25.4% upside, but the stock has already rallied 80% off its low and faces unresolved regulatory and margin sustainability risks. The core thesis is that the company's operational recovery is real but largely priced in, and the stock is likely to trade in a range until clearer evidence emerges on margin normalization and DOJ resolution.
Supporting evidence for the Hold rating includes: (1) the forward PE of 16.90x is at the low end of the historical 19x-29x range, suggesting valuation is undemanding if the recovery holds; (2) Q1 2026 net income of $6.28 billion and EPS of $6.90 represent a dramatic recovery from the Q4 2025 loss, with gross margin rebounding to 22.74% from 16.34%; (3) free cash flow of $8.15 billion in Q1 2026 provides ample liquidity for dividends and buybacks; and (4) the 25.4% upside to the average analyst target is substantial. However, revenue growth of just 1.96% year-over-year and TTM operating margin of 4.24% remain well below historical norms, and the stock's recent underperformance versus SPY (-10.24% over three months) signals waning momentum.
The biggest risks that could invalidate the thesis are: (1) a negative DOJ resolution resulting in material penalties or operational restrictions; (2) a resurgence in medical cost inflation that reverses the margin recovery; and (3) a recession that reduces commercial membership and increases medical utilization. The rating would upgrade to Buy if the forward PE compresses below 15x or if revenue growth accelerates above 4%, and downgrade to Sell if operating margin falls back below 5% or if the DOJ investigation results in criminal charges. Relative to its history and peers, UNH appears fairly valued at 16.9x forward earnings, with the discount to the sector justified by regulatory and growth concerns.
Sign up to view all
UNH 12-Month Price Forecast
UnitedHealth is a high-quality franchise in the midst of a credible but incomplete recovery. The dramatic margin rebound in Q1 2026 and strong free cash flow generation are encouraging, and the forward PE of 16.90x is undemanding if earnings normalize to the $34.29 consensus estimate. However, revenue growth of just 1.96% and the unresolved DOJ investigation create significant uncertainty, and the stock's recent underperformance suggests the easy money from the recovery trade has been made. The risk/reward is balanced at current levels, with 25.4% upside to the average analyst target but 17-33% downside to the bear case. I would upgrade to bullish if the DOJ investigation resolves favorably and operating margins sustainably exceed 8%, or downgrade to bearish if medical cost trends accelerate or revenue growth turns negative.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on UnitedHealth Group's 12-month outlook, with a consensus price target around $481.72 and implied upside of +28.1% versus the current price.
Average Target
$481.72
0 analysts
Implied Upside
+28.1%
vs. current price
Analyst Count
—
covering this stock
Price Range
$380 - $529
Analyst target range
UnitedHealth is covered by 26 analysts with a consensus recommendation of "buy" and a recommendation mean of 1.56 (where 1.0 is a strong buy and 5.0 is a strong sell), indicating a solidly bullish consensus that has weathered the 2025 crisis. The average target price of $475.23 implies 25.4% upside from the current price of $379.09, a substantial gap that suggests analysts believe the market is significantly undervaluing the recovery story. This bullish consensus is notable given the stock's recent underperformance — down 6.53% over one month and 7.20% over three months — implying that analysts see the pullback as a buying opportunity rather than the start of a deeper decline. The consensus leans clearly bullish, with the recommendation mean of 1.56 reflecting a preponderance of buy and overweight ratings across major firms including Truist Securities (Buy), KeyBanc (Overweight), Wells Fargo (Overweight), RBC Capital (Outperform), Morgan Stanley (Overweight), B of A Securities (Buy), Leerink Partners (Outperform), and Mizuho (Outperform), with only TD Cowen and HSBC maintaining Hold ratings. The target price range spans from a low of $313.00 to a high of $529.00, a spread of $216 or 69% of the low target, signaling significant disagreement about the company's trajectory and substantial uncertainty in the analyst community. The high target of $529.00 implies 39.5% upside and assumes full margin normalization, successful resolution of the DOJ investigation, and a return to the premium multiple UNH historically commanded, while the low target of $313.00 implies 17.4% downside and prices in persistent margin pressure, regulatory penalties, or a recession that drives medical cost inflation higher. The institutional ratings data shows a remarkably stable pattern — every firm listed maintained its existing rating with no upgrades or downgrades in the June-July 2026 period — suggesting analysts are in a wait-and-see mode, holding their positions until clearer evidence emerges on margin sustainability and regulatory resolution. The wide target spread combined with the stable ratings pattern indicates that while analysts are collectively bullish, individual conviction varies enormously, and the stock is likely to remain volatile as the market digests quarterly results and regulatory developments.
Drowning in data?
Find the real signal!
Bulls vs Bears: UNH Investment Factors
The bull case rests on a dramatic margin recovery, a historically cheap forward PE of 16.90x, and a 25.4% upside to analyst targets, supported by a powerful free cash flow rebound to $8.15 billion in Q1 2026. The bear case centers on stalled revenue growth of just 1.96%, a stock that has already rallied 80% off its low, and an unresolved DOJ investigation that could impose material penalties. Currently, the bear evidence appears slightly stronger on a near-term basis: the stock is down 6.53% over one month and underperforming SPY by 5.47%, suggesting the recovery trade is losing steam. The single most important tension is whether the margin recovery is sustainable and can drive earnings to the $34.29 consensus EPS estimate, or whether medical cost inflation and regulatory risk will prevent full normalization. If margins hold and the DOJ resolves favorably, the stock could re-rate toward the $475 average target; if not, it risks retesting the $313 low target or worse.
Bullish
- Analyst consensus implies 25% upside: 26 analysts rate UNH a 'buy' with a mean recommendation of 1.56, and the average target price of $475.23 implies 25.4% upside from the current $379.09. The high target of $529.00 implies 39.5% upside, suggesting substantial recovery value remains if margins normalize.
- Margin recovery is dramatic and real: Q1 2026 gross margin rebounded to 22.74% from 16.34% in Q4 2025, while operating margin recovered to 8.05% from just 0.34%. Net income of $6.28 billion in Q1 2026 versus $10 million in Q4 2025 confirms the operational turnaround is underway.
- Forward PE of 16.9x is historically cheap: The forward PE of 16.90x sits at the low end of the 19x-29x range UNH commanded during 2021-2023, and the trailing PE of 24.95x is distorted by the Q4 2025 earnings collapse. If the recovery holds, the market is pricing in permanent impairment that may not materialize.
- Free cash flow rebound is powerful: Q1 2026 free cash flow was $8.15 billion on operating cash flow of $8.91 billion, a dramatic rebound from the anemic $160 million in Q4 2025. TTM free cash flow of $19.67 billion comfortably covers the $2.01 billion quarterly dividend and supports buybacks.
Bearish
- Revenue growth has stalled below 2%: Q1 2026 revenue of $111.72 billion grew just 1.96% year-over-year, a sharp deceleration from historical double-digit growth. Revenue has essentially flatlined around $111-113 billion per quarter since mid-2025, limiting the multiple the market will pay.
- Recovery rally may be fully priced: The stock has rallied roughly 80% off its low and is up 34.39% over six months, yet it trades at just 60.4% of its 52-week range. Recent momentum has turned negative, with the stock down 6.53% over one month and 7.20% over three months, underperforming SPY by 5.47% and 10.24% respectively.
- DOJ investigation remains unresolved: The lingering DOJ investigation is a material regulatory overhang that could result in penalties, operational restrictions, or reputational damage. The wide analyst target spread from $313 to $529 (69% of the low target) reflects significant uncertainty about the outcome.
- TTM margins still well below normal: Trailing twelve-month gross margin of 18.53% and operating margin of 4.24% remain well below the 22-23% gross and 8-9% operating margins UNH routinely delivered in 2023-2024. Full margin normalization has not yet been achieved, and any medical cost inflation could reverse the recovery.
UNH Technical Analysis
UnitedHealth is in a powerful medium-term recovery uptrend that has stalled into a corrective phase, with the stock up 7.21% over the past year and a striking 34.39% over six months, yet trading at just 379.09 — only 60.4% of its 52-week range between a low of 255.97 and a high of 461.62. That positioning, roughly 123 points below the 52-week high but 123 points above the low, places the stock in the middle of its range, suggesting the easy money from the recovery trade has been made and the stock is now searching for direction. The 52-week high of 461.62 remains a distant 21.8% above the current price, meaning buyers from the March lows are still in profit but recent entrants are underwater. Recent momentum has turned decisively negative, with the stock down 6.53% over one month and 7.20% over three months, a sharp deceleration from the 34.39% six-month gain that signals the recovery rally is losing steam. This divergence — strong six-month performance against negative one- and three-month returns — is a classic mean-reversion signal after a parabolic move, and the stock's relative strength versus SPY tells the same story: +18.99% over six months but -5.47% over one month and -10.24% over three months, meaning UNH is now materially underperforming the market after a period of dramatic outperformance. The most recent session saw a 2.37% single-day decline on volume of 7.48 million shares, confirming that selling pressure is intensifying rather than abating. Key technical support sits at the 52-week low of 255.97, with intermediate support likely forming around the 380-390 zone where the stock has repeatedly found buyers in recent weeks; resistance is anchored at the 52-week high of 461.62, and a breakout above that level would signal a full recovery and new leg higher, while a breakdown below 380 would open the door to a retest of the March lows. The stock's beta of 0.622 is a critical risk-management consideration — UNH is roughly 38% less volatile than the broader market, making it a defensive holding that typically declines less in selloffs but also lags in sharp rallies, which partly explains its recent underperformance as the market rotated toward higher-beta names. The maximum drawdown of -29.98% over the period underscores that even low-beta defensive names can experience severe dislocations when fundamentals deteriorate.
Beta
0.62
0.62x market volatility
Max Drawdown
-30.0%
Largest decline past year
52-Week Range
$256-$462
Price range past year
Annual Return
+8.1%
Cumulative gain past year
| Period | UNH Return | S&P 500 |
|---|---|---|
| 1m | -6.4% | -2.4% |
| 3m | -5.9% | +2.2% |
| 6m | +34.1% | +14.8% |
| 1y | +8.1% | +14.6% |
| ytd | +11.8% | +11.1% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
UNH Fundamental Analysis
UnitedHealth's revenue trajectory remains steady but unspectacular, with Q1 2026 revenue of $111.72 billion representing just 1.96% year-over-year growth from $109.58 billion in Q1 2025, a marked deceleration from the double-digit growth rates the company historically delivered. The multi-quarter trend shows revenue essentially flatlining around $111-113 billion per quarter since mid-2025, with Q4 2025 at $113.22 billion, Q3 2025 at $113.16 billion, and Q2 2025 at $111.62 billion — a plateau that reflects membership stability and pricing discipline rather than expansion. Segment data shows UnitedHealthcare contributing $82.99 billion and Optum Health $4.58 billion, confirming that the insurance business remains the overwhelming revenue driver while Optum's care delivery operations represent a much smaller but strategically important piece. The growth stagnation is the central tension in the investment case: without top-line acceleration, the company must rely on margin recovery and capital returns to drive earnings, which limits the upside multiple the market is willing to pay. Profitability has recovered dramatically from the trough, with Q1 2026 net income of $6.28 billion translating to a 5.62% net margin, a massive improvement from the near-zero $10 million net income and 0.01% margin in Q4 2025. Gross margin in Q1 2026 stood at 22.74%, up from 16.34% in Q4 2025 and 18.24% in Q3 2025, while operating margin recovered to 8.05% from just 0.34% in Q4 2025 — a stunning sequential improvement that validates the company's cost management and pricing actions. However, the trailing twelve-month gross margin of 18.53% and operating margin of 4.24% remain well below the 22-23% gross and 8-9% operating margins the company routinely delivered in 2023-2024, indicating that while the worst is past, full margin normalization has not yet been achieved. The balance sheet is solid but not fortress-like, with a debt-to-equity ratio of 0.83, a current ratio of just 0.79 reflecting the insurance business model's low liquidity requirements, and ROE of 12.81% — respectable but below the 20%+ levels UNH historically generated. Free cash flow tells a more encouraging story: Q1 2026 FCF was $8.15 billion on operating cash flow of $8.91 billion, a dramatic rebound from the anemic $160 million FCF in Q4 2025 and $5.06 billion in Q3 2025, with TTM free cash flow of $19.67 billion. The company returned $2.01 billion in dividends in Q1 2026 while carrying $28.00 billion in cash, providing ample liquidity to fund operations and shareholder returns without external financing, though the 65.66% payout ratio and 2.64% dividend yield suggest limited room for aggressive dividend growth without earnings acceleration.
Quarterly Revenue
$111.7B
2026-03
Revenue YoY Growth
+2.0%
YoY Comparison
Gross Margin
22.7%
Latest Quarter
Free Cash Flow
$19.7B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is UNH Overvalued?
Because UnitedHealth is solidly profitable with Q1 2026 net income of $6.28 billion and trailing EPS of $0.04 (distorted by the Q4 2025 earnings collapse), the PE ratio is the appropriate primary metric, though the trailing PE of 24.95x is misleading given the depressed trailing earnings base. The forward PE of 16.90x is far more informative and reflects the market's expectation of a dramatic earnings recovery, with consensus estimated EPS of $34.29 for the forward period implying a normalized earnings power that the trailing figure does not capture. The enormous gap between the trailing PE of 24.95x and forward PE of 16.90x — a 32% compression — signals that analysts expect earnings to roughly double, a recovery thesis that is already substantially reflected in the stock price and leaves limited room for disappointment. On a price-to-sales basis, the stock trades at just 0.67x, remarkably low for a company of this scale and profitability, though this reflects the low-margin nature of the insurance business rather than undervaluation per se. Compared to the broader healthcare sector, UNH's forward PE of 16.90x represents a discount to the market's typical healthcare multiple, but this discount is justified by the company's sub-3% net margin, 1.96% revenue growth, and the lingering regulatory overhang from the DOJ investigation. The EV/EBITDA of 15.37x and EV/Sales of 0.88x are more consistent with a mature, low-growth business than a premium compounder, and the PEG ratio of -1.62 is meaningless given the distorted trailing earnings base. The price-to-book ratio of 3.19x is notably below the 5.0-6.5x range the stock commanded throughout 2022-2024, reflecting both the earnings disruption and the market's reduced willingness to pay a premium for UNH's franchise. Historical ratio data shows the stock's PE ranged from 19x to 29x during 2021-2023, and the current forward PE of 16.90x sits at the low end of that historical band, suggesting the market is pricing in either permanent margin impairment or simply applying a post-crisis discount. The PS ratio of 0.67x is dramatically below the 4.5-6.4x range seen in 2021-2023, though this comparison is distorted by the stock split and the earnings collapse; on a normalized basis, the valuation appears undemanding if the recovery proves durable, but the low multiple also reflects legitimate concerns about regulatory risk and the sustainability of margin recovery.
PE
25.0x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 19x~29x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
15.4x
Enterprise Value Multiple
Investment Risk Disclosure
UnitedHealth faces significant financial and operational risks despite its recovery. The company's revenue growth has stalled at just 1.96% year-over-year in Q1 2026, with revenue flatlining around $111-113 billion per quarter since mid-2025, limiting its ability to grow earnings through top-line expansion. The trailing twelve-month gross margin of 18.53% and operating margin of 4.24% remain well below the 22-23% gross and 8-9% operating margins delivered in 2023-2024, indicating that full margin normalization is not yet assured. The debt-to-equity ratio of 0.83 and current ratio of just 0.79 reflect a leveraged balance sheet with limited liquidity cushion, while the 65.66% dividend payout ratio leaves little room for aggressive dividend growth without earnings acceleration. Additionally, the company's earnings are highly sensitive to medical cost trends, and any resurgence in utilization or cost inflation could quickly reverse the margin recovery.
Market and competitive risks are substantial. UNH trades at a forward PE of 16.90x, which is a discount to the broader healthcare sector, but this discount is justified by the company's sub-3% net margin, 1.96% revenue growth, and the lingering DOJ investigation. The stock's beta of 0.622 means it is less volatile than the market, but it also lags in sharp rallies, as evidenced by its 10.24% underperformance versus SPY over three months. The wide analyst target spread from $313 to $529 (69% of the low target) signals significant disagreement about the company's trajectory, and the stable ratings pattern with no upgrades or downgrades in June-July 2026 suggests analysts are in a wait-and-see mode. Competitive pressures from other managed care organizations and potential regulatory changes to Medicare Advantage reimbursement rates pose ongoing threats. Recent news highlights the stock's 80% rally off its low and the unresolved DOJ investigation, which could cap upside.
The worst-case scenario for UNH would involve a combination of persistent medical cost inflation, a negative DOJ resolution with substantial penalties, and a recession that drives unemployment higher and reduces commercial membership. In this scenario, the stock could retest its 52-week low of $255.97, representing a 32.5% decline from the current price of $379.09. The analyst low target of $313.00 implies a 17.4% downside, but a more severe outcome could see the stock fall to the 52-week low, especially if margins fail to normalize and earnings disappoint. The maximum drawdown of -29.98% over the past period underscores that even low-beta defensive names can experience severe dislocations when fundamentals deteriorate. Investors could lose 17% to 33% from current levels in an adverse scenario, with the downside amplified if the DOJ investigation results in criminal charges or operational restrictions.
FAQ
The most severe risk is the unresolved DOJ investigation, which could result in criminal charges, fines exceeding $5 billion, or operational restrictions that impair the business model. Second, medical cost inflation could reverse the margin recovery, as TTM operating margin of 4.24% remains well below historical norms of 8-9%. Third, revenue growth of just 1.96% year-over-year limits earnings expansion and makes the company vulnerable to any membership losses. Fourth, a recession could drive unemployment higher, reducing commercial membership and increasing medical utilization, while the stock's beta of 0.622 means it will still decline in a broad market selloff, albeit less than high-beta names. Finally, competitive pressures from other managed care organizations could erode pricing power and market share.
Our 12-month forecast assigns a 55% probability to the base case, with a target range of $420-$475, assuming margins stabilize in the 7-8% range and revenue grows 2-4%. The bull case (25% probability) targets $475-$529, driven by a favorable DOJ resolution and full margin normalization to 8-9%. The bear case (20% probability) targets $255-$313, reflecting a resurgence in medical cost inflation, a negative DOJ outcome, and a recession. The most likely scenario is the base case, with the stock appreciating modestly as the recovery continues but facing resistance at the analyst average target of $475. The key assumption is that operating margin sustainably exceeds 7% and the DOJ investigation does not escalate.
UNH appears fairly valued to slightly undervalued on a forward basis. The forward PE of 16.90x is below the 19x-29x range the stock commanded during 2021-2023, and the PS ratio of 0.67x is low for a company of its scale. However, the trailing PE of 24.95x is distorted by the Q4 2025 earnings collapse, and the PEG ratio of -1.62 is meaningless given the depressed trailing earnings. The market is pricing in a substantial earnings recovery to $34.29 per share, and if that materializes, the stock is cheap; if not, the valuation is justified by the low growth and regulatory overhang. Compared to peers, UNH trades at a discount, but that discount reflects its sub-3% net margin and 1.96% revenue growth.
UNH presents a balanced risk/reward for investors with a medium to long-term horizon. The stock trades at a forward PE of 16.90x, which is at the low end of its historical range, and the average analyst target of $475.23 implies 25.4% upside. However, the stock has already rallied 80% off its low and is down 6.53% over the past month, suggesting momentum has faded. The biggest downside risk is the unresolved DOJ investigation, which could result in material penalties and push the stock toward the analyst low target of $313. For value-oriented investors comfortable with regulatory uncertainty, UNH is a reasonable buy at current levels, but those seeking high growth should look elsewhere.
UNH is best suited for long-term investors with a minimum holding period of 2-3 years. The company is in the middle of a multi-year recovery, and the full benefits of margin normalization and regulatory resolution may take time to materialize. The stock's beta of 0.622 makes it a defensive holding, but its recent underperformance versus SPY (-10.24% over three months) shows it can lag in momentum-driven markets. The 2.64% dividend yield and 65.66% payout ratio provide income, but dividend growth is limited without earnings acceleration. Short-term traders may find opportunities around earnings or DOJ news, but the wide analyst target range and regulatory uncertainty make it a risky short-term bet. A long-term horizon allows investors to capture the recovery and potential re-rating.